2025年3月6日 · Harnessing the power of innovative science can help bring new treatments to patients with rare diseases. NS Pharma is developing therapies through exon-skipping, cell …

NS Pharma, Inc. has been developing products to change the way patients and doctors fight rare diseases. VILTEPSO ® (viltolarsen), an exon-skipping therapy designed for patients with …

NS Pharma’s mission is to bring life-changing therapies to patients with rare diseases and serious or life-threatening illnesses or conditions. Expanded Access refers to the use of an …

At NS Pharma, clinical trials follow extensive research and development of candidate compounds. We conduct qualitative assessments with analytical research and then develop pharmaceutical …

Drug discovery and clinical development at NS Pharma happens in concert with our parent company, Nippon Shinyaku. We work in the fields of intractable and rare diseases – …

NS Pharma might be the right company for you. Ask yourself if making the world a better place - one patient at a time - is what you dream about? If so, please browse our career openings and …

At NS Pharma, our leadership team is comprised of diverse, dedicated, knowledgeable and compassionate biotechnology professionals. Empathy and transparency are mission-critical …

PARAMUS, NJ: January 23, 2025 – NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced that Food and Drug Administration (FDA) …

PARAMUS, NJ: March 6, 2024 – NS Pharma, Inc. (NS Pharma) is excited to announce participation in the 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific

Represent NS Pharma at industry conferences, healthcare provider meetings, hospital grand rounds, and patient advocacy events. Engage key stakeholders through effective …